Clinical trials: Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02176538
- Testing
- Product 0405
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic…
- Trial name
- NCT05608343
- Testing
- Difamilast
- Where
- 39 sites in United States
- Volunteers
- 153 people
- Sponsor
- Acrotech Biopharma Inc.
Atopic Dermatitis
Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate…
- Trial name
- NCT04927572
- Testing
- FMX114, Vehicle
- Where
- 7 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis, Eczema
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds.
- Trial name
- NCT00076375
- Testing
- Nanocrystalline silver cream (NPI)
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- Nucryst Pharmaceuticals
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis
The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis.
- Trial name
- NCT02583022
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream vehicle, Elidel cream 1%
- Volunteers
- 74 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
This is a Phase II, multi-centre, randomised, double-blind, placebo-controlled study in male and female subjects, aged ≥ 12 years with mild/moderate atopic dermatitis and at least moderate pruritus.
- Trial name
- NCT01808157
- Testing
- CT327 ointment
- Where
- United Kingdom
- Volunteers
- 188 people
- Sponsor
- Creabilis SA
Mild to Moderate Atopic Dermatitis
CT 327 in the Treatment of Atopic Dermatitis
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT00996008
- Testing
- CT 327
- Where
- 5 sites in Switzerland
- Volunteers
- 15 people
- Sponsor
- Creabilis SA
Atopic Dermatitis
Jaktinib Hydrochloride Cream For Atopic Dermatitis
This study includes a dose escalation part and a dose extension part.
- Trial name
- NCT04435392
- Testing
- Jaktinib Hydrochloride Cream
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Atopic Dermatitis
Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and safety study in subjects with mild to moderate atopic dermatitis.
- Trial name
- C012013 (NCT02031445)
- Testing
- MRX-6
- Where
- 5 sites in Israel
- Volunteers
- 73 people
- Sponsor
- Celsus Therapeutics PLC
Atopic Dermatitis
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04504279
- Testing
- FB-401
- Where
- 15 sites in United States
- Volunteers
- 154 people
- Sponsor
- Forte Biosciences, Inc.